Circadian rhythms are approximately 24-hour cycles in physiology, behavior, and gene expression that are generated by a master clock in the suprachiasmatic nucleus (SCN) of the hypothalamus and synchronized to environmental light-dark cycles. These rhythms regulate sleep-wake cycles, body temperature, hormone secretion, cellular metabolism, and numerous other physiological processes. In Parkinson's disease (PD), circadian dysfunction emerges early, often preceding motor symptoms, and contributes to disease progression through effects on protein homeostasis, neuroinflammation, mitochondrial function, and cellular stress responses. PMID: 41905255
The recognition that circadian disruption is not merely a non-motor symptom of PD but an active driver of pathology has opened new therapeutic avenues. The suprachiasmatic nucleus clock drives molecular clock machinery (CLOCK, BMAL1, PER, CRY) in peripheral tissues including neurons and glia. alpha-Synuclein (alphaSyn) aggregation disrupts this clock machinery, creating a feedforward loop where circadian dysfunction promotes alphaSyn pathology while alphaSyn accumulation further disrupts circadian regulation. PMID: 39707678
Cell-autonomous circadian clocks operate in most cells of the body through a conserved transcriptional-translational feedback loop: PMID: 39539340
Positive Arm: CLOCK and BMAL1 form heterodimers that drive transcription of clock genes including PER (period) and CRY (cryptochrome). RORα competes with REV-ERBα to regulate BMAL1 expression.
Negative Arm: PER (PER1, PER2, PER3) and CRY (CRY1, CRY2) proteins accumulate and inhibit their own transcription by blocking CLOCK-BMAL1 activity. Casein kinase 1ε/δ phosphorylates PER proteins, regulating their stability and nuclear entry.
Auxiliary Loops: Additional interlocking loops involving REV-ERBα, RORα, and NAMPT (nicotinamide phosphoribosyltransferase) provide robustness and tissue-specific modulation of the clock.
The suprachiasmatic nucleus serves as the central pacemaker, receiving direct input from retinal ganglion cells via the retinohypothalamic tract. Light exposure in the evening shifts the phase of SCN neurons through glutamatergic activation. The SCN synchronizes peripheral clocks through neural (autonomic) and humoral (cortisol, melatonin) output pathways.
Almost every cell in the body contains functional molecular clocks that regulate local physiology. In the brain, neurons and glia show circadian rhythms in:
Circadian disruption is extremely common in PD, affecting up to 80% of patients:
Sleep-Wake Cycle Impairment:
Hormone Rhythms: Cortisol, melatonin, and growth hormone secretion show flattened or phase-shifted circadian rhythms in PD.
Activity Rhythms: Rest-activity cycles measured by actigraphy show reduced amplitude, increased fragmentation, and phase advance in PD patients.
Actigraphy-measured rest-activity rhythm parameters correlate with disease severity and progression:
αSyn directly disrupts molecular clock function through multiple mechanisms:
PER2 Dysregulation: PER2, a core clock component, shows altered expression and function in PD. αSyn interacts with PER2, disrupting its transcriptional activity and nuclear localization. PER2 knockdown in neurons recapitulates aspects of the PD molecular phenotype.
BMAL1 Suppression: αSyn accumulation suppresses BMAL1 expression and activity. BMAL1 is a transcription factor that regulates numerous genes including autophagy components. Reduced BMAL1 impairs circadian regulation of autophagy, contributing to protein aggregation.
SIRT1 Disruption: SIRT1 (sirtuin 1), a NAD+-dependent deacetylase that modulates the clock, is dysregulated in PD. αSyn inhibits SIRT1 activity, disrupting the deacetylation of BMAL1 and PER2 that is essential for proper clock function.
The molecular clock and mitochondrial function are tightly linked:
CLOCK-BMAL1 regulate mitochondrial genes: The clock transcription factors regulate expression of mitochondrial biogenesis factors (PGC-1α) and electron transport chain components.
NAD+ rhythms: NAMPT, the rate-limiting enzyme in NAD+ biosynthesis, shows circadian expression. NAD+ levels oscillate over 24 hours, driving rhythms in SIRT1 activity. PD-related mitochondrial dysfunction disrupts NAD+ metabolism, flattening these rhythms.
ROS and the clock: Reactive oxygen species generated by mitochondrial dysfunction can alter clock gene expression, creating a feedforward loop.
Autophagy exhibits strong circadian regulation:
Clock-controlled autophagy genes: The transcription factor BMAL1 regulates expression of autophagy-related genes including LC3, ATG5, and ATG7. This creates circadian rhythms in autophagic flux.
Impaired circadian autophagy in PD: αSyn accumulation disrupts clock-controlled autophagy, flattening the normal rhythm of autophagic activity. This creates periods of reduced clearance capacity that coincide with peak αSyn aggregation.
Time-of-day effects: Studies in PD models suggest that αSyn pathology is more severe when autophagy is at its circadian nadir, suggesting time-of-day dependent vulnerability.
Post-mortem studies reveal SCN involvement in PD:
PD affects circuits that regulate circadian function:
Basal ganglia circuits: The basal ganglia, central to motor dysfunction in PD, also regulate sleep-wake cycles. Dopaminergic dysfunction in these circuits contributes to sleep fragmentation.
Locus coeruleus involvement: The locus coeruleus (LC), which regulates arousal and attention, shows early pathology in PD. LC dysfunction contributes to fragmented sleep and excessive daytime sleepiness.
Orexin/hypocretin loss: Orexin-producing neurons in the lateral hypothalamus are reduced in PD, contributing to sleep-wake dysfunction and narcolepsy-like symptoms.
The enteric nervous system (ENS), which shows early αSyn pathology in PD, contains functional circadian clocks that regulate gastrointestinal function. Disruption of ENS clocks may contribute to the constipation and other GI symptoms that often precede motor PD.
Circadian disruption may actively worsen PD pathology:
Sleep deprivation and αSyn aggregation: Fragmented sleep and reduced slow-wave sleep impair glymphatic clearance, allowing αSyn oligomers to accumulate. Studies show that sleep deprivation increases extracellular αSyn and promotes aggregation.
Oxidative stress amplification: Disrupted circadian regulation of antioxidant responses (Nrf2 pathway) makes neurons more vulnerable to oxidative stress during certain times of day.
Inflammatory amplification: Circadian disruption enhances neuroinflammatory responses. NF-κB activity shows circadian regulation; disruption amplifies pro-inflammatory cytokine production.
Metabolic dysregulation: Misaligned feeding rhythms and disrupted hormone rhythms impair cellular metabolism, creating additional stress for vulnerable neurons.
The normal nighttime period involves:
Circadian disruption predicts faster cognitive decline in PD:
Depression and anxiety in PD show circadian patterns:
Cardiovascular circadian rhythms are disrupted in PD:
Timing of medications: Aligning PD medications with circadian phases may enhance efficacy. Levodopa taken at circadian peak (typically morning) may be more effective.
Light therapy: Bright light exposure in the morning helps entrain circadian rhythms. Light therapy has shown benefit for sleep and mood in PD patients.
Melatonin: Melatonin supplementation in the evening can help phase-align circadian rhythms and improve sleep initiation in PD patients.
SIRT1 activators: Resveratrol and synthetic SIRT1 activators may restore circadian function by enhancing BMAL1 acetylation/deacetylation cycling.
NAMPT activators: boosting NAD+ biosynthesis may restore SIRT1 rhythms and improve metabolic function.
REV-ERB agonists: Synthetic REV-ERB agonists enhance BMAL1 repression and may improve circadian amplitude. SR9009 and similar compounds are in preclinical testing for PD.
Continuous positive airway pressure (CPAP): For PD patients with sleep apnea, CPAP treatment improves sleep quality and may reduce circadian disruption.
Sodium oxybate: Xyrem (sodium oxybate) has been explored for RBD in PD, improving sleep consolidation.
Orexin antagonists: Suvorexant and similar orexin receptor antagonists may improve sleep in PD, though they require careful titration.
Polymorphisms in clock genes have been associated with PD risk:
LRRK2 (leucine-rich repeat kinase 2), the most common genetic cause of familial PD, interacts with circadian regulation:
Mutations in PARKIN and PINK1 cause autosomal recessive PD and show circadian dysfunction:
The core body temperature rhythm is a reliable marker of circadian function:
PD patients show multiple temperature rhythm abnormalities:
Temperature dysregulation in PD involves:
Body temperature monitoring using wearable sensors can serve as a circadian biomarker in PD. Rest-activity and temperature wearable data may help stratify patients by circadian phenotype and monitor therapeutic response.
Chronobiotics for PD: New drug candidates that enhance circadian amplitude (chronobiotics) are being tested in PD models.
Circadian biomarkers: Wearable devices measuring temperature, activity, and heart rate variability may serve as non-invasive biomarkers for PD progression.
Light therapy optimization: Understanding the optimal wavelength, timing, and intensity of light therapy for PD patients.
Meal timing interventions: Time-restricted feeding aligned with circadian rhythms may benefit PD patients, based on emerging evidence in other neurodegenerative conditions.
Circadian dysfunction is a pervasive and underappreciated feature of PD that contributes to disease progression through multiple interconnected mechanisms:
Therapeutic targeting of circadian dysfunction through chronotherapy, light exposure, melatonin, chronobiotics, and sleep optimization represents an emerging approach to disease modification in PD. The circadian system offers multiple "druggable" targets and the potential for non-pharmacological interventions that can be personalized to individual patients.
The following diagram shows the key molecular relationships involving Circadian Dysregulation in Parkinson's Disease discovered through SciDEX knowledge graph analysis: